BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Type 2 diabetes clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for type 2 diabetes: 370 (175 sponsors; 109 newly posted in the last 180 days, 7 stopped in the last 180 days; 37 new-entrant sponsors). Momentum score 31.1, rank 5 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 54, Phase 2 68, Phase 3 112, Phase 4 21, N/A 114.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Eli Lilly and Company LLY32P3 17, P1 5, P2 7, P4 395
Novo Nordisk A/S NVO35NA 10, P3 12, P1 7, P2 4, P4 2173
AstraZeneca AZN18P3 11, P1 3, NA 3, P2 1135
Amgen AMGN9P1 2, P3 6, P2 133
Gan & Lee Pharmaceuticals.9P2 2, P3 5, P1 211
Hoffmann-La Roche9P3 5, P2 2, P1 1, NA 140
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.8P3 5, P2 1, P4 201
EMS4P3 400
Viking Therapeutics, Inc. VKTX4P3 420
Pfizer PFE3P3 310
Jiangsu HengRui Medicine Co., Ltd.5P2 2, P3 2, P1 122
Boehringer Ingelheim3P3 2, NA 111
The United Bio-Technology (Hengqin) Co., Ltd. new entrant3P3 2, P1 130
Beijing Dongfang Biotech Co., Ltd.2P3 200
BrightGene Bio-Medical Technology Co., Ltd.2P3 211
Guangdong Raynovent Biotech Co., Ltd2P3 202
Jiangsu Hansoh Pharmaceutical Co., Ltd.2P3 202
Daewoong Pharmaceutical Co. LTD.6P1 1, NA 4, P3 110
Fujian Shengdi Pharmaceutical Co., Ltd.6P1 3, P3 1, P2 235
Boryung Pharmaceutical Co., Ltd4NA 2, P4 1, P3 102
Dong-A ST Co., Ltd.3P2 1, P4 1, P3 101
Addpharma Inc. new entrant2P1 1, P3 120
CSPC Ouyi Pharmaceutical Co., Ltd.2P3 1, P2 110
Hanmi Pharmaceutical Company Limited HAFC2P3 1, P2 100
Vertex Pharmaceuticals Incorporated VERX2P3 1, P2 101

New-entrant sponsors: The United Bio-Technology (Hengqin) Co., Ltd., Addpharma Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3Boryung Pharmaceutical Co., LtdNCT06220773 A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyEssential Hypertension; Type 2 Diabetes Mellitusrecruiting276
2026-12 est.P3CelltrionNCT07093476 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminT2DM; Diabete Type 2; DMrecruiting171
2026-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT07487103 Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 DiabetesType 2 Diabetesnot yet recruiting478
2026-12-01 est.P3Guangdong Raynovent Biotech Co., LtdNCT07139535 A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneT2DMnot yet recruiting350
2026-12-01 est.P3Guangdong Raynovent Biotech Co., LtdNCT07139548 A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 DiabetesT2DMnot yet recruiting600
2027-01-21 est.P3Amgen AMGNNCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightType 2 Diabetes Mellitus (T2DM), Obesity, Overweightactive not recruiting1105
2027-02 est.P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT07060456 Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinType 2 Diabetesrecruiting300
2027-02 est.P2Antag TherapeuticsNCT07724340 A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and OverweighAdults With Overweight/Obesity and Type 2 Diabetesactive not recruiting150
2027-02-11 est.P2Gan & Lee Pharmaceuticals.NCT07387003 Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 DiabetesType 2 Diabetes (T2DM)not yet recruiting345
2027-02-14 est.P3Hudson BiotechNCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbiditiesrecruiting2539
2027-02-16 est.P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07082114 A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes MellitusType 2 Diabetesrecruiting800

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-04 est.P3CMG Pharmaceutical Co. LtdNCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and DyslipidemiaDyslipidemia; Type 2 Diabetesrecruiting240
2026-11-04P3THPharm Corp.NCT06647745 A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THPType 2 Diabetes; Hypertensionactive not recruiting222
2026-10-30 est.P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT07026968 A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 DiabetesType 2 Diabetesactive not recruiting815
2026-10-26P3Eli Lilly and Company LLYNCT06297603 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on BaType 2 Diabetesactive not recruiting341
2026-10-18 est.P2/P3Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB ChairNCT07033585 Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled CancersType 2 Diabetesactive not recruiting600
2026-10-10 est.P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07193459 Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes MellitusType 2 Diabetesrecruiting360
2026-10 est.P2Housey Healthcare ULCNCT07546929 HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 DiabetesType 2 Diabetesrecruiting300
2026-09-18P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes MellitusObese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Losscompleted58
2026-09-18P3Gan & Lee Pharmaceuticals.NCT06778967 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)completed1133
2026-09-01 est.P3Daewoong Pharmaceutical Co. LTD.NCT06606093 Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsType 2 Diabetic Nephropathynot yet recruiting348
2026-08-25P3BrightGene Bio-Medical Technology Co., Ltd.NCT06716216 A Study of BGM0504 in Participants With Type 2 DiabetesType 2 Diabetes Mellitus (T2DM)completed553
2026-08-13P2Zealand Pharma ZEAL.CONCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)Overweight; Type 2 Diabetes; Obesitycompleted221
2026-08-13P3BrightGene Bio-Medical Technology Co., Ltd.NCT06716203 A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseType 2 Diabetes Mellitus (T2DM)completed227
2026-08-10P2Ascletis Pharma (China) Co., LimitedNCT07321678 A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusT2DM (Type 2 Diabetes Mellitus)completed100
2026-07-30P3Gan & Lee Pharmaceuticals.NCT06777238 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by DiType 2 Diabetes Mellitus (T2DM)completed274
2026-07-18P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2Type 2 Diabetescompleted884
2026-07-06P2Eli Lilly and Company LLYNCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2Dcompleted134
2026-07 est.P3EMSNCT05028140 Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes MellitusType II Diabetesrecruiting480
2026-07 est.P3EMSNCT04670666 Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes MellitusType 2 Diabetes Mellitusrecruiting270
2026-06-29P3Novo Nordisk A/S NVONCT07271251 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People WiType 2 Diabetescompleted267
2026-06-28 est.P2Gan & Lee Pharmaceuticals.NCT07055386 A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)active not recruiting90
2026-06-16P3Eli Lilly and Company LLYNCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightType 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apneacompleted1152
2026-05-29P2Carmot Therapeutics, Inc.NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusOverweight or Obese; Type 2 Diabetes Mellitus (T2DM)completed447
2026-05-29P3Shandong Suncadia Medicine Co., Ltd.NCT06589765 A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With MetforminType 2 Diabetescompleted810
2026-05-27P2NodThera Ltd. (a Rezera company)NCT07055516 Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusObesity and Type 2 Diabetescompleted176

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "type 2 diabetes"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.